Search hospitals
>
South Carolina
>
Greer
Prisma Health Cancer Institute - Greer
Claim this profile
Greer, South Carolina 29650
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
249 reported clinical trials
8 medical researchers
Summary
Prisma Health Cancer Institute - Greer is a medical facility located in Greer, South Carolina. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Prisma Health Cancer Institute - Greer is involved with conducting 249 clinical trials across 407 conditions. There are 8 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Suzanne R. Fanning.
Area of expertise
Breast Cancer
Prisma Health Cancer Institute - Greer has run 48 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Prisma Health Cancer Institute - Greer has run 39 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Ki Chung, MD
Prisma Health Cancer Institute - Eastside
6 years of reported clinical research
Aniket Saha
BI-LO Charities Children's Cancer Center
8 years of reported clinical research
Jeffrey K. Giguere
Prisma Health Cancer Institute - Faris
8 years of reported clinical research
Suzanne R. Fanning
Prisma Health Cancer Institute - Eastside
2 years of reported clinical research
Clinical Trials running at Prisma Health Cancer Institute - Greer
Breast Cancer
Lung Cancer
Breast cancer
Cancer
Bladder Cancer
Colorectal Cancer
Testicular cancer
Kidney Cancer
Pancreatic Cancer
Non-Small Cell Lung Cancer
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting
2 awards
Phase 3
19 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting
2 awards
Phase 3
40 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting
2 awards
Phase 3
8 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Prisma Health Cancer Institute - Greer?
Prisma Health Cancer Institute - Greer is a medical facility located in Greer, South Carolina. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Prisma Health Cancer Institute - Greer is involved with conducting 249 clinical trials across 407 conditions. There are 8 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Suzanne R. Fanning.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.